Interim Results to Be Presented at International Academic Conference

GC Cell will present interim results from the Phase 1a trial of GCC2005, an allogeneic CAR-NK cell therapy targeting refractory T-cell lymphoma, at an international academic event specializing in lymphoma. The company will share with Korean lymphoma experts data released at the American Society of Hematology (ASH) annual meeting last year and plans to announce the full Phase 1a data by the end of this year.


GC Cell: "Full Phase 1a Data on CAR-NK Therapy to Be Released by Year-End" View original image

On October 28, GC Cell said it will present the development process for GCC2005 and interim Phase 1a results at the international academic event "2026 KLWP-EBML," held to mark the 20th anniversary of the Lymphoma Working Party of the Korean Society of Hematology. The presentation will be given by Professor Ko Young-il of Seoul National University Hospital.


GCC2005 is an allogeneic CAR-NK cell therapy targeting the CD5 protein. It is being developed as an "off-the-shelf" treatment that can be manufactured in advance using NK cells from another person. GC Cell gave an oral presentation on interim Phase 1a results at ASH 2025 last December. At the time, five of eight patients with relapsed or refractory NK/T-cell lymphoma who had received at least three prior lines of treatment responded, resulting in an objective response rate of 62.5%. Three of those patients achieved complete remission, with no detectable cancer.


GC Cell is currently conducting a Phase 1b trial in Korea, aiming to develop a first-in-class drug. It plans to present the full Phase 1a data at a major international medical conference by the end of this year.



GC Cell CEO Won Seong-yong said, "We are continuing discussions with experts by sharing clinical data and development updates at major conferences in Korea and abroad. We will advance the ongoing Phase 1b trial without disruption and move toward global development."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing